Bavarian Nordic A/S (BVNRY)
OTCMKTS: BVNRY · Delayed Price · USD
8.77
+0.73 (9.08%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Bavarian Nordic Employees
Bavarian Nordic had 1,379 employees as of December 31, 2023. The number of employees increased by 404 or 41.44% compared to the previous year.
Employees
1,379
Change (1Y)
404
Growth (1Y)
41.44%
Revenue / Employee
$700,895
Profits / Employee
$103,845
Market Cap
2.05B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BVNRY News
- 1 day ago - Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine - GlobeNewsWire
- 9 days ago - Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine - GlobeNewsWire
- 26 days ago - Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan - GlobeNewsWire
- 4 weeks ago - Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa - GlobeNewsWire
- 4 weeks ago - Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA - GlobeNewsWire
- 5 weeks ago - Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate - GlobeNewsWire
- 2 months ago - Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine - GlobeNewsWire
- 2 months ago - Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa - GlobeNewsWire